Skip to main content
. 2021 Mar 8;12:630773. doi: 10.3389/fimmu.2021.630773

Figure 3.

Figure 3

NCOR1 mutations were associated with enhanced tumor immunogenicity, higher immune scores and activated immune cells. (A, B) Comparison of TMB (A) and NAL (B) between NCOR1-MT and NCOR1-WT tumors in the TCGA-BLCA cohort. (C) Comparison of DNA damage-related gene set alterations between NCOR1-MT and NCOR1-WT tumors in the TCGA-BLCA cohort. (D–G), Comparison of leukocyte fraction (D), TIL regional fraction (E), lymphocyte infiltration signature score (F) and ESTIMATE-derived scores (G) between NCOR1-MT and NCOR1-WT tumors in the TCGA-BLCA cohort. (H) Comparison of immune cells between NCOR1-MT and NCOR1-WT tumors in the TCGA-BLCA cohort. Gene expression profiles were prepared using standard annotation files, and data were uploaded to the CIBERSORT web portal (http://cibersort.stanford.edu/), with the algorithm run using the LM22 signature and 1,000 permutations. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ns, not significant. (A–H) Mann–Whitney U test). TMB, tumor mutation burden; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; BLCA, bladder urothelial carcinoma; NCOR1, nuclear receptor corepressor 1; MT, mutant; WT: wild-type.